Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.